NeurologyAmyloid drugs, a second look
New data reopen the debate over who benefits from anti-amyloid antibodies.
Clara Whitfield · 31 October 2026
Tag
Alzheimer's
Neurology
Trial NewsSeven phase 3 readouts to watch this quarter
From obesity to Alzheimer's, the trials that could move markets.
Clara Whitfield · 26 October 2026